Skip to main content
. 2015 Dec 24;7(4):3847–3856. doi: 10.18632/oncotarget.6758

Figure 4. Effect of EGFR-TKI treatment in LMC models with HCC827/luc and H1975/luc cells.

Figure 4

HCC827/luc and H1975/luc cells were inoculated into the space between the external occipital protuberance and first cervical vertebra of SHO-SCID mice. (A, B) Production of LMC was determined using the IVIS imaging system; MST: median survival time. (C) The mice inoculated with HCC827/luc cells were daily treated with control (N = 3) or AZD9291 (6 mg/kg) (N = 4) from day 18 until day 36. (D) The mice inoculated with H1975/luc cells were daily treated with control (N = 3) or AZD9291 (6 mg/kg) (N = 3) from Daily oral treatment with AZD9291 (6 mg/kg) was given from day 5 until day 22.